Evidence map›Paper›PMID 36817852›Full record

ReviewBiochemia medica2023

Laboratory medicine in arterial hypertension.

Merica Aralica, Vesna Šupak-Smolčić, Lorena Honović, Lucija Franin, Pavica Šonjić, Maja Šimac, Mihovil Horvat, Nina Poropat

Open access · diamondAbstract readReview
In one paragraph

Review in Biochemia medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Merica AralicaClinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Vesna Šupak-SmolčićClinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Lorena HonovićDepartment of Medical Biochemistry and Laboratory Medicine, General Hospital Pula, Pula, Croatia.
Lucija FraninClinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Pavica ŠonjićClinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Maja ŠimacClinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Mihovil HorvatClinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Nina PoropatDepartment of Endocrinology, Diabetes and Metabolic Disorders, Clinical Hospital Centre, Rijeka, Croatia.
University of Rijeka · HRCS Diagnostics · DEDiabetes Australia · AUJuraj Dobrila University of Pula · HRUniversity Hospital Centre Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the initial diagnostics of arterial hypertension (AH) laboratory medicine is a cornerstone, along with a blood pressure (BP) measurement and an electrocardiogram. It mainly refers to routine blood and urine tests for diagnosis and monitoring primary hypertension and its associated conditions such as asymptomatic hypertension-mediated organ damage, chronic kidney disease and hypertensive disorders of pregnancy. In addition, long term non-fatal and fatal risks for cardiovascular (CV) events in hypertension are assessed based on clinical and laboratory data. Furthermore, laboratory medicine is involved in the management of hypertension, especially in monitoring the disease progression. However, antihypertensive drugs may interfere with laboratory test results. Diuretics, especially thiazides, can affect blood and urine sodium concentrations, or angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can affect the blood biomarkers of the renin-angiotensin-aldosterone system (RAAS). It's dysfunction plays a critical role in primary aldosteronism (PA), the most common endocrine disorder in secondary hypertension, which accounts for only small proportion of AH in relative terms but substantial proportion of hypertensives in absolute terms, affecting younger population and carrying a higher risk of CV mortality and morbidity. When screening for PA, aldosterone-to-renin ratio still contributes massively to the increased incidence of the disease, despite certain limits. In conclusion, laboratory medicine is involved in the screening, diagnosis, monitoring and prognosis of hypertension. It is of great importance to understand the preanalytical and analytical factors influencing final laboratory result.

Indexed as

HypertensionAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsHumansPrognosisRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAntihypertensive Agentsantihypertensive agentclinical laboratory testhypertensionmedical laboratory science

Identifiers

PMID36817852
PMCPMC9927727
OpenAlexW4319025274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.